--with monocytes and lymphocytes--

## **IN THE CLAIMS**

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

- 10. (Amended) The reagent according to any claim 2, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.
- 20. (Amended) The method according to claim 12, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.
- 31. (Amended) The diagnostic agent according to claim 23, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

SHITARA, K. et al. Serial No. unknown national phase of PCT/JP00/03957

- 42. (Amended) The diagnostic method according to claim 34, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.
- 53. (Amended) The inhibitor of migration of a monocyte and/or a macrophage according to claim 45, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.
- 65. (Amended) The therapeutic agent according to claim 57, wherein the antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.